摘要
恩杂鲁胺（enzalutamide）是由Medivation公司和安斯泰来（Astellas）公司合作开发，于2012年8月31日经美国食品药品管理局（FDA）批准用于治疗已扩散或复发的晚期男性去势耐受前列腺癌（castration-resistantprostatecancer），商品名为Xtandi，该药为口服制剂。
出处
《中国药物化学杂志》
CAS
CSCD
2013年第1期79-79,共1页
Chinese Journal of Medicinal Chemistry
参考文献6
-
1Jung M E,Ouk S,Yoo D,et al.Structure-activity relationshipfor thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)[].Journal of Medicinal Chemistry.2010
-
2TRAN C,OUK S,CLEGG N,et al.Development of a second generation antiandrogen for treatment of advanced prostate cancer[].Science.2009
-
3SAWYERS C,JUNG M,CHEN C,et al.Diarylhydantoin com-pounds[].WO.2006
-
4JUNG M,YOO D,SAWYERS C,et al.Diarylthiohydantoin compounds[].US.2007
-
5THOMPSON A,LAMBERSON C,GREENFIELD S,et al.Processes for the synthesis of diarylthiohydantoin and diarylthiohydantoin compounds[].WO.2011
-
6JUNG M,OUK S,SAWYERS C,et al.Methods and materials for assessing prostate cancer therapies and compounds[].US.2008
同被引文献36
-
1宋丽君,王飏,陆旭芳,李志裕.雄激素受体拮抗剂MDV3100的合成研究[J].精细化工中间体,2012,42(1):34-36. 被引量：7
-
2崔福德.药剂学[M].北京:人民卫生出版社,2008:311-314.
-
3TRAN C,OUK S,CLEGG N,et al. Development of a second generation antiandrogen for treatment of ad- vanced prostate cancer [J]. Science,2009,324(5928).. 787-790.
-
4CHARLES kS,MICHAEL EJ,CHARLIE DC,et al. Di- arylhydantoin Compounds: US, 7709517 [ P ].2010-05-04.
-
5HOWARD L SCHER,KARIM FIZAZI,FRED SAAD, et al. Increased survival with enzalutamide in prostate af- ter chemotherapy[OL]. N Engl Med: 2012-8-15.
-
6FOSSA SD, SLEE PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomati- cally progressing after androgen-ablative therapy: a phase III study of the European organization for re- search and treatment of cancer genitourinary group [J]. J Clin Oncol,2001,19(1 ) :62-71.
-
7AKAZA H,HINOTSU S,USAMI M,et al. Study group for the combined androgen blockade therapy of prostate cancer combined androgen blockade with hiealutamide for advanced prostate cancer: long-term follow-up of a phase 3,double-blind,randomized study for survival [ J ]. Cancer, 2009 ; 115 ( 15 ) : 3437-3445.
-
8CRAWFORI) E D,EISENBERGER M A,MCLEOD DG,et al. A controlled trial of leuprolide with and with- out flutamide in prostatic carcinoma[J]. N Engl J Med, 1989,321 (7) :419-424.
-
9CHEN CD,WELSBIE DS,TRAN C,et al. Molecular determinants of resistance to antiandrogen therapy [J]. Nat Med, 2004,10( 1 ) : 33-39.
-
10KOLVENBAG GJ,FURR BJ,BLACKLEDGE GR. Re- ceptor affinity and potency of non-steroidal antiandro- gens: translation of preclinical findings into clinical activity [J]. Prostate Cancer Prostatic Dis, 1998(6): 307-314.
二级引证文献5
-
1曾令康,冯菊红,葛燕丽,冯丽,熊刚,张兰馨,胡学雷.4-异硫氰基-2-(三氟甲基)苯甲腈的合成[J].化学与生物工程,2016,33(4):33-36.
-
2黄敏玉,黄群,吴军.前列腺癌内分泌治疗的研究进展[J].右江医学,2016,44(2):225-228. 被引量：2
-
3冯丽,冯菊红,胡学雷.HPLC法测定恩杂鲁胺原料药的含量[J].湖北大学学报（自然科学版）,2017,39(6):673-676.
-
4楠迪,云志中.种族差异性与前列腺癌基因组易感性的研究进展[J].临床医药文献电子杂志,2019,6(6):194-195. 被引量：2
-
5万涛,周治军,徐康,杨军,熊标.circ-0026462靶向miR-361-3p调控前列腺癌细胞对恩杂鲁胺耐药性的机制研究[J].国际泌尿系统杂志,2022,42(5):797-802.
-
1王淑明（编译）.类风湿关节炎的医疗管理（二）[J].中国全科医学（医生读者版）,2009(2):62-63.
-
2钱坤.冬季疫苗总动员[J].健康,2004,0(12):30-32.
-
3沈德莉.口服青霉素也要做皮试[J].家庭用药,2001(4):36-36.
-
4益生菌 补多了也有害[J].中南药学（用药与健康）,2015(10).
-
5苏州滋露药业有限公司简介[J].抗感染药学,2008,5(1).
-
6周健,司继刚.氨溴索注射剂和口服制剂合并使用引起医患纠纷一例[J].实用药物与临床,2016,19(3):391-392. 被引量：3
-
7陆晓骅,晏马成.我院2006～2008年抗菌药物使用情况分析[J].中国医药导报,2009,6(12):124-126.
-
8小药箱里放什么[J].齐鲁护理杂志,2009,15(2S):23-23.
-
9乐栎,张红婴（图）.补救：把孩子颠来倒去[J].中国家庭医生,2005(11S):39-39.
-
10苏州滋露药业有限公司简介[J].抗感染药学,2008,5(4).
